Brief: Kintor Pharmaceutical Expects To Commence Phase III Clinical Trial Of Kx-826 In China In Q4
08/09/2021 15:13
Sept 8 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* EXPECTS TO COMMENCE PHASE III CLINICAL TRIAL OF KX-826 IN
CHINA
IN Q4 OF 2021
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint